BIODESIX, INC.

PREDICTIVE TEST FOR PROGNOSIS OF MYELODYSPLASTIC SYNDROME PATIENTS USING MASS SPECTROMETRY OF BLOOD-BASED SAMPLE

#2 | 2023-02-28 ✅ Patent 11,594,403 granted on 2023-02-28

US15899866

Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample

#3 | 2023-01-05 ✅ Patent 11,894,147 granted on 2024-02-06

US20230005621A1

Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings

#4 | 2023-01-03 ✅ Patent 11,542,340 granted on 2023-01-03

US17514737

Chemistry; metallurgy

Antibodies targeting pulmonary nodule specific biomarkers and uses thereof

#5 | 2022-10-27

US20220341939A1

PREDICTIVE TEST FOR IDENTIFICATION OF EARLY STAGE NSCLC STAGE PATIENTS AT HIGH RISK OF RECURRENCE AFTER SURGERY

#6 | 2022-06-16 ✅ Patent 11,476,003 granted on 2022-10-18

US20220189638A1

Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings

#7 | 2022-06-16

US20220188701A1

INTERPRETATION OF MACHINE LEARNING CLASSIFICATIONS IN CLINICAL DIAGNOSTICS USING SHAPELY VALUES AND USES THEREOF

#8 | 2022-06-02 ✅ Patent 12,247,980 granted on 2025-03-11

US20220170938A1

Compositions, methods and kits for diagnosis of lung cancer

#9 | 2022-04-07 ✅ Patent 11,621,057 granted on 2023-04-04

US20220108771A1

Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy

#10 | 2022-01-27

US20220026416A1

METHOD FOR IDENTIFICATION OF CANCER PATIENTS WITH DURABLE BENEFIT FROM IMMUNOTEHRAPY IN OVERALL POOR PROGNOSIS SUBGROUPS

#11 | 2021-04-22 ✅ Patent 12,094,587 granted on 2024-09-17

US20210118538A1

Apparatus and method for identification of primary immune resistance in cancer patients

#12 | 2021-04-01 ✅ Patent 12,230,398 granted on 2025-02-18

US20210098131A1

Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods

#13 | 2020-11-05 ✅ Patent 11,467,167 granted on 2022-10-11

US20200348310A1

SRM methods in Alzheimer's disease and neurological disease assays

#14 | 2019-11-21 ✅ Patent 11,150,238 granted on 2021-10-19

US20190353645A1

Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups

#15 | 2019-09-24 ✅ Patent 10,422,729 granted on 2019-09-24

US16296918

Blood sample separation devices and methods

#16 | 2019-01-17 ✅ Patent 11,710,539 granted on 2023-07-25

US20190018929A1

Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy

#17 | 2018-11-08 ✅ Patent 10,217,620 granted on 2019-02-26

US20180323049A1

Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry

#18 | 2018-09-27 ✅ Patent 10,950,348 granted on 2021-03-16

US20180277249A1

Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods

#19 | 2018-07-19 ✅ Patent 10,870,891 granted on 2020-12-22

US20180202005A1

Chemistry; metallurgy

Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole blood

#20 | 2018-05-10 ✅ Patent 10,489,550 granted on 2019-11-26

US20180129780A1

Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample

#21 | 2018-03-08 ✅ Patent 11,913,957 granted on 2024-02-27

US20180067119A1

Compositions, methods and kits for diagnosis of lung cancer

#22 | 2018-03-01 ✅ Patent 10,802,027 granted on 2020-10-13

US20180059113A1

Compositions, methods and kits for diagnosis of lung cancer

#23 | 2018-01-11 ✅ Patent 11,193,935 granted on 2021-12-07

US20180011099A1

Compositions, methods and kits for diagnosis of lung cancer

#24 | 2017-09-21 ✅ Patent 10,593,529 granted on 2020-03-17

US20170271136A1

Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies

#25 | 2017-07-27 ✅ Patent 10,534,002 granted on 2020-01-14

US20170212120A1

Selected reaction monitoring assays

#26 | 2017-02-09 ✅ Patent 10,007,766 granted on 2018-06-26

US20170039345A1

Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods

#27 | 2017-02-07 ✅ Patent 9,563,744 granted on 2017-02-07

US14949229

Method of predicting development and severity of graft-versus-host disease

#28 | 2016-11-03 ✅ Patent 10,713,590 granted on 2020-07-14

US20160321561A1

Bagged filtering method for selection and deselection of features for classification

#29 | 2016-06-16 ✅ Patent 10,338,074 granted on 2019-07-02

US20160169900A1

Compositions, methods and kits for diagnosis of lung cancer

#30 | 2016-06-09 ✅ Patent 10,037,874 granted on 2018-07-31

US20160163522A1

Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry

#31 | 2016-04-07 ✅ Patent 9,779,204 granted on 2017-10-03

US20160098514A1

Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample

#32 | 2016-01-21 ✅ Patent 9,606,101 granted on 2017-03-28

US20160018410A1

Deep MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof

#33 | 2015-10-08 ✅ Patent 9,211,314 granted on 2015-12-15

US20150283206A1

Treatment selection for lung cancer patients using mass spectrum of blood-based sample

#34 | 2015-04-16 ✅ Patent 9,477,906 granted on 2016-10-25

US20150102216A1

Classification generation method using combination of mini-classifiers with regularization and uses thereof

#35 | 2014-01-09 ✅ Patent 8,718,996 granted on 2014-05-06

US20140012514A1

Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents

#36 | 2013-12-26 ✅ Patent 9,653,272 granted on 2017-05-16

US20130344111A1

Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies

#37 | 2013-12-05 ✅ Patent 9,279,798 granted on 2016-03-08

US20130320203A1

Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof

#38 | 2013-06-18 ✅ Patent 8,467,988 granted on 2013-06-18

US13733018

Method and system for validation of mass spectrometer machine performance

#39 | 2013-05-23 ✅ Patent 9,254,120 granted on 2016-02-09

US20130131996A1

Method for predicting breast cancer patient response to combination therapy

#40 | 2012-08-02 ✅ Patent 8,914,238 granted on 2014-12-16

US20120193525A1

Method for predicting breast cancer patient response to endocrine therapy

#41 | 2012-04-12 ✅ Patent 9,152,758 granted on 2015-10-06

US20120089341A1

Method and system for determining whether a drug will be effective on a patient with a disease

#42 | 2012-03-29 ✅ Patent 8,586,380 granted on 2013-11-19

US20120074311A1

Monitoring treatment of head and neck cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples

#43 | 2012-03-29 ✅ Patent 8,586,379 granted on 2013-11-19

US20120074310A1

Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples

#44 | 2010-12-02 ✅ Patent 9,824,182 granted on 2017-11-21

US20100305868A1